GlassScriptPhysician profile
David R Enis
NPI 1154441624
$7,411.73
in general payments reported to CMS, 2019-2025
27 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $779 · 2021: $356 · 2022: $892 · 2023: $1,305 · 2024: $1,700 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,979 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.20 |
| Education | $225.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,152.72 | 2019-2025 | Tremfya |
| Abbvie INC. | $953.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $694.82 | 2019-2025 | |
| Leo Pharma INC. | $544.22 | 2019-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $494.65 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $422.72 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Vyne Pharmaceuticals INC. | $394.12 | 2020-2021 | |
| Incyte Corporation | $343.85 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $319.67 | 2019-2025 | Sotyktu |
| Amgen INC. | $317.19 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $270.03 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $261.40 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $235.73 | 2019-2025 | |
| Pfizer INC. | $221.74 | 2019-2025 | |
| Lilly USA, LLC | $219.66 | 2019-2025 | Olumiant, Taltz, Ebglyss |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $106.43 | 2025 | Vtama |
| Celgene Corporation | $88.63 | 2019 | |
| Prugen, INC. Pharmaceuticals | $81.87 | 2019-2020 | |
| Dermavant Sciences, INC. | $75.20 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.10 | 2022-2023 | Spevigo |
| Ucb, INC. | $42.06 | 2024-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $28.91 | 2019-2022 | |
| Dusa Pharmaceuticals, INC. | $19.95 | 2019 | |
| Epi Health, LLC | $17.59 | 2021 | |
| Sandoz INC. | $17.24 | 2019 | |
| Biofrontera INC. | $16.66 | 2019 | |
| Journey Medical Corporation | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Enis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.